Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NG6420 | Other Grant/Funding Number | NG6420 | |
| NG6420 | Other Grant/Funding Number | Nil Guler |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators hypothesized that Non Hodgkin lymphoma is using T helper 2 pathways. So that the investigators decided to study of cytokines related to T helper 2 pathways. It is well known that parasites and allergic situations also use T helper 2 pathways. Because that the investigators excluded the patients have parasites and allergic situations. All the patients were over 18. The investigators included the patients with non Hodgkin lymphoma which new diagnosed. It is observational study. The investigators took blood before chemotherapy and four months later. The investigators did not interfere with which chemotherapy will be given to patients. This decision was belong to hematologist or oncologist who will treat the patient.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lymphoma group | |||
| healthy group | |||
| IL-10 high | |||
| IL-10 low | |||
| IL-4 high | |||
| IL-4 low | |||
| lymphopenia |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Interleukin 4 and Interleukin 10 levels as pg/mL in non hodgkin lymphoma | We will measure 31 patients and 27 healthy person's Interleukin 4 and Interleukin 10 levels as pg/mL at the beginning of the study. We determined all of the patients IPI score, LDH (U/L), crp (mg/L), erythrocyte sedimentation rate, hemoglobin (gr/dL), lymphocyte count in per µL, albumin (gr/dL) before the treatment. We wanted to check whether there is any correlation between well known prognostic markers (LDH, crp, albumin, stage, ECOG performance status) and Interleukin-4 and interleukin-10 levels. | This study ended within 13 months |
| Measure | Description | Time Frame |
|---|---|---|
| survey as months | Our secondary goal was to determine the survey time as month from diagnoses to die from any reason or last evaluation during our study which was 13 months. | During study which was 13 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
31 newly diagnosed non hodgkin lymphoma and 27 healthy controls. We studied IL-10 and IL-4 in lymphoma group and healthy group and observed patients till end of study. We analised survival. We compared with IL-4 and IL-10 levels with prognostic factors.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nil Guler, MD | Principal Investigator | |
| Nil Guler, MD | ONDOKUZ MAYİS UNİVERSİTY, SCHOOL OF MEDİCİNE | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ondokuz Mayis University Medical School | Samsun | Atakum | 55139 | Turkey (Türkiye) |
Not provided
| Label | URL |
|---|---|
| OMU School of Medicine. Contact via e-mail. | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D008223 | Lymphoma |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
Not provided
Not provided
periperal blood sample
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |